Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 11, 2010

Qiagen to Distribute Celera’s ResPlex II Multiplex Assay for Respiratory Pathogens

  • Qiagen negotiated exclusive, worldwide distribution rights to Celera’s next-generation ResPlex II multiplex assay for the detection of respiratory pathogens. The new assay detects 19 different pathogens and is designed for use with the Luminex LiquiChip 100 and 200 instrument platforms, for which Qiagen is also a partner. The test has yet to be submitted for regulatory approval in the U.S. and Europe.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »